SimBioSys, a clinical AI company that uses spatial biophysics to help make breast cancer treatments more precise, has signed a strategic, non-exclusive agreement with Ricoh 3D for Healthcare, LLC. Ricoh 3D for Healthcare is part of Ricoh USA, Inc. and makes FDA-approved, patient-specific medical devices both in central facilities and at the point of care. This partnership is meant to make TumorSight Viz, SimBioSys’s FDA-approved 3D surgical visualization tool for breast cancer surgery, more widely available.
Health Technology Insights: Pulse Biosciences Shares First Human Data on Thyroid Nodule Treatment
TumorSight Viz takes standard breast MRI scans and converts them into clear, easy-to-understand 3D images that show the size, location, and relationship of the tumor with surrounding tissues. This helps surgeons make more informed and personalized decisions during surgery. The latest version, TumorSight Viz 1.3, is known for being very accurate in identifying tumors, delivering results quickly within minutes, and connecting smoothly with hospital Picture Archiving and Communication Systems (PACS) to make surgical planning and teamwork easier.
This collaboration follows TumorSight Viz 1.3 receiving FDA 510(k) clearance and shows both companies’ shared goal of making advanced digital health tools available to a larger audience. By combining SimBioSys’s innovative software with Ricoh’s strong healthcare services, connections with surgical oncologists, and nationwide distribution, both companies plan to speed up the use of AI-based surgical visualization tools in breast cancer care.
Health Technology Insights: Verasonics, ImFusion Partner to Advance Clinical Ultrasound
Stacey Stevens, President and CEO of SimBioSys, is excited about the partnership and stressed the company’s commitment to providing innovations that help clinicians make more accurate and tailored surgical choices. Stevens praised Ricoh for its wide reach, strong reputation, and dedication to advancing surgical innovation, saying Ricoh is well-suited to help extend TumorSight Viz’s use to more medical teams and patients. She added that this partnership addresses the growing need for tools that improve surgical results, reduce difference in outcomes, and enhance the experience for both healthcare professionals and patients.
Derek Mathers, Director of Clinical Applications at Ricoh 3D for Healthcare, pointed out the difficulties breast surgeons face in removing tumors effectively while preserving the patient’s quality of life. Mathers said Ricoh is committed to developing patient-specific solutions that help doctors strike this balance. He explained that working with SimBioSys allows Ricoh to offer TumorSight Viz as a tool that improves clarity in planning surgeries, supports oncoplastic techniques, expands options for breast conservation, and leads to more consistent results for patients. Clinical research has shown that TumorSight Viz works well with radiologist evaluations, accurately measures tumor size in relation to breast volume, and performs consistently across over 1,600 cases from more than nine medical centers. These results highlight the platform’s reliability and readiness for wider clinical use. Ricoh 3D for Healthcare will help bring TumorSight Viz to the market as part of its commitment to offering innovative, patient-centered solutions.
Health Technology Insights: Acadia Names Konstantina Katcheves as Senior VP
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
